Gagnon Securities LLC Has $3.45 Million Holdings in ICU Medical, Inc. $ICUI

Gagnon Securities LLC lessened its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 11.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,751 shares of the medical instruments supplier’s stock after selling 3,564 shares during the period. Gagnon Securities LLC owned approximately 0.12% of ICU Medical worth $3,449,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Inscription Capital LLC grew its holdings in ICU Medical by 407.9% in the 3rd quarter. Inscription Capital LLC now owns 8,365 shares of the medical instruments supplier’s stock valued at $1,003,000 after buying an additional 6,718 shares in the last quarter. Emerald Mutual Fund Advisers Trust bought a new stake in shares of ICU Medical in the third quarter valued at about $1,096,000. Simon Quick Advisors LLC acquired a new position in shares of ICU Medical in the second quarter valued at about $275,000. AlphaQuest LLC increased its position in ICU Medical by 3,058.3% during the second quarter. AlphaQuest LLC now owns 1,516 shares of the medical instruments supplier’s stock worth $200,000 after acquiring an additional 1,468 shares during the period. Finally, Aaron Wealth Advisors LLC bought a new position in ICU Medical during the third quarter worth about $521,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of ICU Medical in a research report on Thursday, January 22nd. Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a research note on Monday, January 19th. Piper Sandler increased their price target on ICU Medical from $153.00 to $172.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Finally, KeyCorp lifted their price objective on ICU Medical from $173.00 to $175.00 and gave the company an “overweight” rating in a report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $175.67.

Insider Activity

In other ICU Medical news, Director Elisha W. Finney sold 1,285 shares of the business’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $140.42, for a total transaction of $180,439.70. Following the completion of the transaction, the director owned 3,995 shares of the company’s stock, valued at approximately $560,977.90. The trade was a 24.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Virginia Ruth Sanzone sold 930 shares of the stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $142.34, for a total transaction of $132,376.20. Following the completion of the transaction, the vice president directly owned 5,456 shares of the company’s stock, valued at $776,607.04. This trade represents a 14.56% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 1.50% of the company’s stock.

ICU Medical Stock Performance

Shares of NASDAQ:ICUI opened at $150.03 on Friday. The company’s 50 day simple moving average is $148.27 and its 200 day simple moving average is $133.33. The stock has a market capitalization of $3.70 billion, a price-to-earnings ratio of -483.95 and a beta of 0.80. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.45 and a quick ratio of 1.19. ICU Medical, Inc. has a 1 year low of $107.00 and a 1 year high of $173.85.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share for the quarter, topping the consensus estimate of $1.43 by $0.60. The firm had revenue of $533.30 million during the quarter, compared to analysts’ expectations of $511.46 million. ICU Medical had a positive return on equity of 7.71% and a negative net margin of 0.32%.The company’s quarterly revenue was down 8.9% on a year-over-year basis. During the same period in the prior year, the company earned $1.59 earnings per share. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. As a group, research analysts predict that ICU Medical, Inc. will post 4.11 EPS for the current fiscal year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.